Dentsply Sirona announced on February 11, 2025, that it has initiated a process to evaluate strategic alternatives for its Wellspect Healthcare business. Wellspect is a leading provider of bladder and bowel management care products with over 40 years of history.
Wellspect Healthcare has demonstrated strong performance, delivering mid-to-high single-digit organic sales growth for 2023 and through the first three quarters of 2024. The business operates in the continence care space, which has an estimated $2 billion total addressable market.
CEO Simon Campion stated that this step aims to unlock significant potential value for stakeholders, allowing Dentsply Sirona to focus resources on its core dental business. Goldman Sachs & Co. LLC is serving as the financial advisor for this strategic review.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.